Early transition to oral therapy in gram-negative bloodstream infections: what is the next step?
Clinical Microbiology and Infection · 2024
DOI: 10.1016/j.cmi.2024.01.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Microbiology and Infection, 2024. Verfasst von Lucía Boix-Palop und 1 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Hospital Universitari Mútua de Terrassa, Barcelona, Spain; University of Medicine, Universitat Internacional de Catal…. Hauptthemen laut MEDLINE: Sepsis, Gram-Negative Bacterial Infections, Bacteremia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: European Society of Clinical Microbiology and Infectious Diseases.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Department, Hospital Universitari Mútua de Terrassa, Barcelona, Spain; University of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain. Electronic address: luciaboix@hotmail.com.
- Infectious Diseases Department, Hospital Universitari Mútua de Terrassa, Barcelona, Spain; University of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain.
Förderung
- European Society of Clinical Microbiology and Infectious Diseases
Zitieren
APA
Boix-Palop, L., & Calbo, E. (2024). Early transition to oral therapy in gram-negative bloodstream infections: what is the next step?. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2024.01.002
Vancouver
Boix-Palop L, Calbo E. Early transition to oral therapy in gram-negative bloodstream infections: what is the next step?. Clinical Microbiology and Infection. 2024. doi:10.1016/j.cmi.2024.01.002
BibTeX
@article{BoixPalop2024,
author = {Boix-Palop, Lucía and Calbo, Esther},
title = {Early transition to oral therapy in gram-negative bloodstream infections: what is the next step?},
journal = {Clinical Microbiology and Infection},
year = {2024},
doi = {10.1016/j.cmi.2024.01.002}
}
EUVIMED